Article
Oncology
Zheng Li, Juan Zheng, Yang Feng, Yaming Li, Yiran Liang, Ying Liu, Xiaolong Wang, Qifeng Yang
Summary: Long noncoding RNAs play a crucial role in cancer aerobic glycolysis, with potential implications in breast cancer progression. By identifying glycolysis-related lncRNAs in breast cancer cells and assessing their expression levels in different conditions, this study reveals their impact on cancer initiation and progression. Furthermore, the study explores the use of a prognostic signature including lncRNAs and clinical features, providing insights into potential therapeutic targets for breast cancer patients.
Article
Oncology
Lixiang Feng, Jun Yang, Wei Zhang, Xiong Wang, Lili Li, Min Peng, Pengcheng Luo
Summary: Based on the importance of the basement membrane (BM) in cancer invasion and metastasis, this study constructed a BM-associated lncRNA risk model for bladder cancer (BCa) patients. The model accurately predicted prognosis, tumor invasion, and metastasis, and showed good predictive power for the tumor microenvironment and mutational burden. The study provides new insights into predicting prognosis and understanding the molecular mechanisms of BCa.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Ting Zhu, Junjun Wang, Juan Li, Qichao Zhang, Yanyan Shang, Junhao Zhou, Ling Min, Bo Lv, Kai Luo
Summary: In this study, researchers identified a LncRNA signature associated with the prognosis of TNBC patients using RNA-sequencing analysis and qRT-PCR assay. The signature showed a significant correlation with shorter overall and progression-free survival time in the validation cohorts. Therefore, this signature has the potential to be a prognostic marker for TNBC.
CLINICA CHIMICA ACTA
(2023)
Review
Pharmacology & Pharmacy
Jinlan Chen, Enqing Meng, Yexiang Lin, Yujie Shen, Chengyu Hu, Gang Zhou, Chengfu Yuan
Summary: PART1, a member of lncRNA, plays either a promoting or inhibitory role in tumors by regulating various molecular mechanisms such as microRNA targeting, protein expression regulation, and signal pathway modulation. It can serve as a clinical marker for early diagnosis and a key target in tumor targeted therapy.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Oncology
Zan Li, Junyi Yu, Chunliu Lv, Zhenhua Luo
Summary: This study identified 95 CAF-specific lncRNAs and proposed a FibLnc score based on immune cell transcriptome expression profiling data. The FibLnc score was found to predict overall patient survival, correlate with clinical stage in breast cancer patients, and predict immunotherapy response. These findings provide insights into the potential therapeutic decisions and regulatory mechanisms of CAF-specific lncRNAs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yunxiang Zhang, Xiaotong Dong, Yang Wang, Liquan Wang, Guiyan Han, Lvcheng Jin, Yanping Fan, Guodong Xu, Dawei Yuan, Jie Zheng, Xiangyu Guo, Peng Gao
Summary: This study revealed that the expression of lncRNA BM466146 in breast cancer tissues was significantly lower than in normal tissues, while its overexpression was associated with better prognosis. BM466146 may regulate CXCL-13 by adsorbing hsa-miR-224-3p, inducing the accumulation of CD8(+) T cells in the tumor area to modulate immune response.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Jinfeng Zhang, Siyu Hou, Zilong You, Guozheng Li, Shouping Xu, Xianyong Li, Xianyu Zhang, Bo Lei, Da Pang
Summary: The study analyzed the expression and prognostic values of the ARID family in breast cancer, revealing differences in expression levels and outcomes among different molecular subtypes. Some ARID members were associated with favorable outcomes, while others were associated with worse outcomes.
Article
Cell Biology
Jin Hu, Haohao Huang, Zihan Xi, Shenghui Ma, Jie Ming, Fang Dong, Hui Guo, Huiqiong Zhang, Ende Zhao, Guojie Yao, Liu Yang, Feng Zhang, Wuping Zheng, Hengyu Chen, Tao Huang, Lei Li
Summary: In this study, the researchers investigated the functional role of a novel long noncoding RNA SEAS1 in breast cancer progression. They found that SEAS1 was downregulated in TNBC tissues and its knockdown increased the proliferation, migration, and invasion of TNBC cell lines. They also discovered that SEAS1 acted as a sponge for miR-3940-3p, preventing the degradation of its target gene KLLN, which acts as a tumor inhibitor. Additionally, they demonstrated that SMAD3 directly interacted with the promoter of SEAS1 and suppressed its transcription, thereby promoting TNBC progression. Their findings suggest that SEAS1 may serve as a potential biomarker and therapeutic target for TNBC.
CELL DEATH & DISEASE
(2022)
Review
Pharmacology & Pharmacy
Bei Wang, Wen Xu, Yuxuan Cai, Kai Liu, Jiacheng Wu, Chong Guo, Chengfu Yuan
Summary: This review summarizes the molecular mechanisms of lncRNA BCAR4 in different cancers, highlighting its important role in cancer development and potential clinical value as a therapeutic target.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Immunology
Wenchang Lv, Yufang Tan, Xiaomei Zhou, Qi Zhang, Jun Zhang, Yiping Wu
Summary: This study establishes a predictive signature based on glycosyltransferase-related lncRNAs (GT-lncRNAs) in breast cancer prognosis and response to immune checkpoint inhibitors (ICIs) treatment. The risk score calculated from the coefficients of 8 GT-lncRNAs can divide breast cancer patients into high- and low-risk groups, with the high-risk group showing shorter survival and the risk score being an independent predictor of breast cancer prognosis. The risk score can also stratify patients with distinct immune infiltration and patients in the high-risk group might benefit more from ICIs treatment. The well-constructed prognostic signature with GT-lncRNAs provides reliable tools for predicting breast cancer outcomes and making rational follow-up strategies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Lili Zhu, Kang Cui, Lanling Weng, Pu Yu, Yabing Du, Tengfei Zhang, Hong Liu, Bingjie Li, Wang Ma
Summary: Breast cancer is a common cancer among females worldwide, and recent studies have shown the potential of lncRNAs as independent biomarkers for diagnosis and prognosis in various types of cancer. The study identified a panel of 8 lncRNAs with prognostic value in BCa, showing that patients with low risk scores had better overall survival and the lncRNA signature was an independent prognostic factor. Gene Set Enrichment Analysis suggested the involvement of lncRNAs in key molecular pathways related to BCa.
Article
Mathematical & Computational Biology
Yun-xiang Li, Shi-ming Wang, Chen-quan Li
Summary: The study identified four immune-related lncRNAs (RP11-890B15.3, RP11-1024P17.1, MFI2-AS1, and RP11-180N14.1) with independent prognostic value in TNBC patients. A prognostic risk model based on these lncRNAs effectively predicted patient survival outcomes. High-risk patients demonstrated enriched immune response and infiltrating immune cells, while specific lncRNAs regulated mRNA by targeting various miRNAs. These findings suggest that the identified lncRNAs could serve as prognostic biomarkers and potential therapeutic targets in TNBC.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2021)
Article
Cell Biology
Yuan Huang, Xiaowei Wang, Yiran Zheng, Wei Chen, Yabing Zheng, Guangliang Li, Weiyang Lou, Xiaojia Wang
Summary: This study established a novel competing endogenous RNA network to predict prognosis in TNBC patients. Through differential gene expression analysis, key miRNAs, upregulated miRNAs, key lncRNAs, and others were identified, forming a complex network involving mRNAs, miRNAs, and lncRNAs.
Article
Biochemistry & Molecular Biology
Tingting Yan, Chaoqin Shen, Penglei Jiang, Chenyang Yu, Fangfang Guo, Xianglong Tian, Xiaoqiang Zhu, Shiyuan Lu, Bingshe Han, Ming Zhong, Jinxian Chen, Qiang Liu, Yingxuan Chen, Junfang Zhang, Jie Hong, Haoyan Chen, Jing-Yuan Fang
Summary: The study identified a risk SNP-mediated oncogene lncRNA-SLCC1 that promotes colorectal cancer by activating the glycolysis pathway, with its expression levels associated with patient survival.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Junlong Wang, Dionyssios Katsaros, Nicoletta Biglia, Yuanyuan Fu, Chiara Benedetto, Lenora Loo, Zhanwei Wang, Herbert Yu
Summary: ZNF582-AS1 expression is lower in breast cancer and is associated with poor disease-free and overall survival. It may be involved in cell cycle and cell death regulation and act as a sponge for the oncogenic miRNA miR-940. The expression of ZNF582-AS1 may be repressed by HIF-1-related transcription factors.